TY - JOUR
T1 - The most effective and promising population health strategies to advance human papillomavirus vaccination
AU - Jacobson, Robert M.
AU - Agunwamba, Amenah A.
AU - St. Sauver, Jennifer L.
AU - Rutten, Lila J.Finney
N1 - Funding Information:
Authors of this work have been supported by the National Institutes of Health (AG034676 and UL1RR024150) and the Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery. RM Jacobson serves on safety review committees for Merck & Co for two studies of human papillomavirus vaccine safety and on a Data Monitoring Committee for studies of pneumococcal vaccine immunogenicity and safety. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
Publisher Copyright:
© 2015 Taylor & Francis.
PY - 2016/2/1
Y1 - 2016/2/1
N2 - The US is failing to make substantive progress toward improving rates of human papillomavirus vaccine uptake. While the Healthy People 2020 goal for human papillomavirus (HPV) vaccination is 80%, the three-dose completion rate in the US in 2014 for 13- to 17-year-old females is less than 40%, and the rate for males is just above 20%. Experts point to a number of reasons for the poor HPV vaccination rates including parental concerns about safety, necessity, and timing. However, the evidence refuting these concerns is substantial. Efforts focusing on education and communication have not shown promise, but several population health strategies have reminder/recall systems; practice-focused strategies targeting staff, clinicians, and parents; assessment and feedback activities; and school-based HPV vaccination programs.
AB - The US is failing to make substantive progress toward improving rates of human papillomavirus vaccine uptake. While the Healthy People 2020 goal for human papillomavirus (HPV) vaccination is 80%, the three-dose completion rate in the US in 2014 for 13- to 17-year-old females is less than 40%, and the rate for males is just above 20%. Experts point to a number of reasons for the poor HPV vaccination rates including parental concerns about safety, necessity, and timing. However, the evidence refuting these concerns is substantial. Efforts focusing on education and communication have not shown promise, but several population health strategies have reminder/recall systems; practice-focused strategies targeting staff, clinicians, and parents; assessment and feedback activities; and school-based HPV vaccination programs.
KW - Papillomavirus vaccines
KW - United States
KW - adolescent
KW - child
KW - health knowledge, attitudes, practice
KW - immunization
KW - immunization programs
KW - vaccination
UR - http://www.scopus.com/inward/record.url?scp=84955648388&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84955648388&partnerID=8YFLogxK
U2 - 10.1586/14760584.2016.1116947
DO - 10.1586/14760584.2016.1116947
M3 - Review article
C2 - 26559567
AN - SCOPUS:84955648388
SN - 1476-0584
VL - 15
SP - 257
EP - 269
JO - Expert Review of Vaccines
JF - Expert Review of Vaccines
IS - 2
ER -